Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 28/01/2021

    Carl Zeiss Foundation funds Interdisciplinary practice Study at Heidelberg University with the sum of approximately of 4.5 Million Euros

    Can interconnected digital assistance systems enhance the quality of life of people in older age? Scientists in an interdisciplinary research project at Heidelberg University are exploring this question in a representative practice study. The participating researchers want to investigate how well these technical aids can be used and what benefit they achieve.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/carl-zeiss-foundation-funds-interdisciplinary-practice-study-heidelberg-university-sum-approximately-45-million-euros
  • Funding

    JOINT TRANSNATIONAL CALL 2021

    Funding programme, Funded by: Horizon 2020, Submission deadline: 04/03/2021
    https:////www.gesundheitsindustrie-bw.de/en/database/funding/joint-transnational-call-2021
  • Funding

    INNO4COV-19 Project

    Funding programme, Funded by: Horizon 2020, Submission deadline: 31/03/2021
    https:////www.gesundheitsindustrie-bw.de/en/database/funding/inno4cov-19-project
  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Funding

    TRANSVAC: New Vaccines Faster

    Funding programme, Funded by: Horizon2020, Submission deadline: 15/12/2020
    https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/transvac-new-vaccines-faster
  • Press release - 09/11/2020

    European TRIANKLE project will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joint

    The Research consortium is composed of 12 partners from 5 European countries and counts with a EU funding of €5.9M. TRIANKLE will provide fabrication of personalized implants for injured tendons or cartilages. Fraunhofer IGB will formulate and develop collagen- and gelatine-based bio-inks needed for 3D printing the personalised implants.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/european-triankle-project-will-develop-3d-bioprinted-personalised-scaffolds-tissue-regeneration-ankle-joint
  • Press release - 04/11/2020

    Which treatment is best for childhood brain tumors? Global trial receives funding of EUR 2.2m

    The German Childhood Cancer Foundation is providing EUR 2.2m to fund the phase III clinical trial to investigate the treatment options for certain types of childhood brain cancer with a chronic course. Initiated by the Hopp Children’s Cancer Center Heidelberg, the trial will compare two standard chemotherapy treatments and a targeted therapy to establish which is the most effective and well tolerated as a standard therapy for young patients.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/welche-behandlung-ist-die-beste-bei-hirntumoren-im-kindesalter-weltweite-studie-wird-mit-22-mio-euro-gefoerdert
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 08/10/2020

    New class of highly effective inhibitors protects against neurodegeneration

    Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-class-highly-effective-inhibitors-protects-against-neurodegeneration
  • Press release - 25/09/2020

    Bosch’s new rapid coronavirus test delivers reliable results in 39 minutes

    Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/boschs-new-rapid-coronavirus-test-delivers-reliable-results-39-minutes
  • Press release - 15/09/2020

    ELLIS inaugurates 30 research units at leading institutions across Europe

    At a virtual event on Tuesday, the European Laboratory for Learning and Intelligent Systems presented the broad scope of research its units will cover in the field of modern AI.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-offizieller-start-der-30-forschungseinheiten-fuehrenden-institutionen-ganz-europa
  • Press release - 07/09/2020

    Cyber Valley launches Investor Network

    Europe’s largest AI research consortium attracts interest from some of the world’s most successful venture capital firms.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-gruendet-investor-network
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
  • Press release - 15/06/2020

    German Federal Government invests 300 Million Euros in CureVac

    The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
  • Innovations in the field of endoscopy - 08/06/2020 Computeranimation der Kamerapille im Dünndarm.

    Gastroscopies with pill cameras

    A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille
  • Translational oncology - 26/05/2020 NCT_181204_3435.jpg

    Translation: driver of cancer medicine

    The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
  • Press release - 13/05/2020

    Corona antibody tests from Reutlingen

    The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/corona-antikoerpertests-aus-reutlingen
  • Press release - 27/04/2020

    EIT Health pledges €6m funding to accelerate COVID-19 solutions

    EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eit-health-pledges-eur6m-funding-accelerate-covid-19-solutions
  • Prime Vector Technologies GmbH - 09/04/2020 Kleineres_Original_fuer_Kachel_Corona_AdobeStock_318040586_Kopie.jpg

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Funding

    Novartis announces broad range of initiatives to respond to COVID-19 Pandemic

    Funding programme, Funded by: Novartis AG
    https:////www.gesundheitsindustrie-bw.de/en/database/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
  • Biotech start-up from Frickenhausen develops chewing gum as test system for bacteria - 19/12/2019

    A medical connoisseur – the tongue as a sensor for infections

    The start-up 3a-diagnostics GmbH from Frickenhausen is developing a gum that can be used both in doctors’ surgeries and at home as a quick and easy diagnostic aid. The sensor in this case is the human tongue. If bacteria are present – due to an inflammation of the teeth or tonsils, for instance – chewing produces a bitter taste and the doctor can quickly initiate the appropriate treatment.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/medizinischer-feinschmecker-die-zunge-als-sensor-fuer-infektionen
  • Company profile - 16/12/2019 Ausschnitt aus dem Mikrofluidik-System von Velabs, das dicht gepackt ist mit einzelnen Tröpfchen

    Velabs Therapeutics GmbH: each droplet is a test system

    Using microfluidics to detect new therapeutic antibodies is, in simple terms, the concept developed by Velabs Therapeutics GmbH. The Heidelberg-based start-up was spun out from the European Molecular Biology Laboratory (EMBL) in 2017 with the support of EMBLEM Technology Transfer GmbH. More recently, investors have provided the young company with additional funding to expand its technologies and applications.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/velabs-therapeutics-gmbh-each-droplet-test-system
  • Press release - 28/08/2019

    Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies

    Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.

    https:////www.gesundheitsindustrie-bw.de/fachbeitrag/pm/immatics-and-celgene-enter-strategic-collaboration
  • Freiburg im Breisgau - 04/06/2019

    Spindiag’s continued road to success: Expansion of Series A with an additional 4 million euros for market entry

    Spindiag, a young medtech company in the German state of Baden-Württemberg, announced today the expanded financing of its first Series A. Based on a proprietary microfluidic technology first researched at the company’s mother institute Hahn-Schickard, Spindiag is developing a sustainable platform to diagnose infections and, as a first product, a rapid test for multidrug-resistant bacteria.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/spindiags-continued-road-to-success-expansion-of-series-a-with-an-additional-4-million-euros-for-market-entry

Page 1 / 27

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 27
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search